The University of Tokyo's new coronavirus drug candidate Fusan clinical research begins May 8 at 18:32
The University of Tokyo announced that it has begun clinical research to confirm the safety and efficacy of `` fusan, '' which has been used for the treatment of acute pancreatitis, which is a candidate for a new coronavirus therapeutic agent, and to confirm its safety and efficacy. .
The University of Tokyo administers the drug "Husan", which has been used to treat acute pancreatitis and diseases that cause blood clots in various parts of the body, and the generic name "Nafamostat" to patients with pneumonia infected with the new coronavirus. Announced that they have begun clinical research.
The clinical study was conducted on 160 patients at 6 medical facilities in Japan, such as the University of Tokyo Hospital. A group of patients receiving influenza drug "Abigan" and "Fusan" and only "Abigan" were administered. Divide into groups and confirm safety and effectiveness.
The University of Tokyo says that experiments using the new coronavirus have shown that "Fusan" can be expected to suppress the growth of the virus.
In addition, some patients report that the formation of blood clots leads to the worsening of symptoms, so the research group said that "Fusan", which has the effect of preventing blood from clotting, can be expected. I will.
“I think that I have entered the clinical research as soon as possible since the announcement of the results. I would like to expect the results to reach the drug to many patients,” said Junichiro Inoue, a specially appointed professor of the University of Tokyo who showed the possibility of effectiveness.